A
Andrew C. Embleton
Researcher at University College London
Publications - 15
Citations - 1211
Andrew C. Embleton is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Bevacizumab. The author has an hindex of 11, co-authored 15 publications receiving 956 citations. Previous affiliations of Andrew C. Embleton include University of London.
Papers
More filters
Journal ArticleDOI
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M. Oza,Adrian Cook,Jacobus Pfisterer,Andrew C. Embleton,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Tjoung Won Park-Simon,Gordon J. S. Rustin,Florence Joly,Mansoor Raza Mirza,Marie Plante,Michael A. Quinn,Andres Poveda,Gordon C Jayson,Dan Stark,Ann Marie Swart,Laura Farrelly,Richard Kaplan,Mahesh K. B. Parmar,Timothy J. Perren +23 more
TL;DR: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression, so evidence of non-proportional hazards was shown.
Journal ArticleDOI
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann,Andrew C. Embleton,Fharat A. Raja,Timothy J. Perren,Gordon C Jayson,Gordon J. S. Rustin,Stan B. Kaye,Hal W. Hirte,Elizabeth Eisenhauer,Michelle D. Vaughan,Michael Friedlander,Antonio González-Martín,Dan Stark,Elizabeth Clark,Laura Farrelly,Ann Marie Swart,Adrian Cook,Richard Kaplan,Mahesh K.B. Parmar +18 more
TL;DR: Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful improvement in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with added toxic effects.
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
J. A. Ledermann,Timothy J. Perren,Fharat A. Raja,Andrew C. Embleton,Gjs Rustin,Gordon C Jayson,S. B. Kaye,Ann Marie Swart,Michelle Margaret Vaughan,H. Hirte +9 more
Journal ArticleDOI
Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes
Stefan Kommoss,Boris Winterhoff,Boris Winterhoff,Ann L. Oberg,Gottfried E. Konecny,Chen Wang,Shaun M. Riska,Jian-Bing Fan,Matthew J. Maurer,Craig April,Viji Shridhar,Friedrich Kommoss,Andreas du Bois,Felix Hilpert,Sven Mahner,Klaus Baumann,W. Schroeder,Alexander Burges,Ulrich Canzler,Jeremy Chien,Andrew C. Embleton,Mahesh K. B. Parmar,Richard Kaplan,Timothy J. Perren,Lynn C. Hartmann,Ellen L. Goode,Sean C. Dowdy,Jacobus Pfisterer +27 more
TL;DR: Validation of the findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost.
Journal ArticleDOI
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
Ann Rita Halvorsen,Gunnar B. Kristensen,Andrew C. Embleton,Cybil Adusei,Maria Pilar Barretina-Ginesta,Philip Beale,Åslaug Helland +6 more
TL;DR: Interestingly, low level of miR-200c was associated with 5-month prolongation of PFS when treated with bevacizumab compared to standard chemotherapy when treating patients with epithelial ovarian cancer, and prognostic significance was found in all histological types.